Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Progyny, Inc. (NASDAQ:PGNY) has earned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $29.6667.

A number of analysts have issued reports on the company. Zacks Research lowered Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 5th. Barclays boosted their target price on Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. KeyCorp cut their target price on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Citizens Jmp upped their price objective on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research report on Monday, May 11th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research report on Monday, May 11th.

Progyny Price Performance

Shares of Progyny stock opened at $26.63 on Friday. The stock has a market cap of $2.09 billion, a P/E ratio of 34.58, a P/E/G ratio of 2.26 and a beta of 1.03. The stock’s 50 day simple moving average is $21.46 and its 200-day simple moving average is $22.30. Progyny has a 1-year low of $16.10 and a 1-year high of $28.75.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.24. The business had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts expect that Progyny will post 1.07 EPS for the current fiscal year.

Progyny announced that its board has authorized a share repurchase program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Progyny

In other news, insider Geoffrey Clapp sold 1,530 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total transaction of $39,137.40. Following the sale, the insider owned 59,117 shares of the company’s stock, valued at approximately $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark S. Livingston sold 2,517 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total value of $64,183.50. Following the sale, the chief financial officer directly owned 74,688 shares in the company, valued at $1,904,544. This represents a 3.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 36,916 shares of company stock valued at $939,875. Insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

Large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new position in Progyny in the fourth quarter valued at $25,000. Hantz Financial Services Inc. increased its holdings in Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after buying an additional 742 shares during the last quarter. Quarry LP increased its holdings in Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after buying an additional 3,427 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in Progyny in the second quarter valued at $77,000. Finally, New Age Alpha Advisors LLC purchased a new position in Progyny in the fourth quarter valued at $94,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.